Merck & Co., Inc. (MRK) stock analysis

Merck & Co., Inc. — Healthcare · Drug Manufacturers—General carries a Plainview business-quality score of 7.3/10, built deterministically from SEC filings and Yahoo Finance: revenue, margins, cash, valuation, and a confluence buy zone. The live X-Ray loads below.

On the fundamentals, Merck & Co., Inc. shows trailing revenue of $66.57B, a 75.9% gross margin, net debt of $42.72B, EPS of 1.88, valued at about 5.3x times sales. X-Ray measures business quality only — momentum and entry timing live in Decide and Opportunity Cost.

• Current Price: $143.93
• YTD Return: +35.2%
• Revenue TTM: $66.57B
• Revenue Trend: YoY +5.1%
• Gross Margin: 75.9%
• Net Cash: $-42.72B
• EPS: 1.88
• P/S Ratio: 5.3x

Compare: MRK vs UNH · MRK vs JNJ · MRK vs LLY | Also: UNH, JNJ, LLY, PFE, ABBV, TMO